Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Oncotarget ; 7(34): 55128-55140, 2016 Aug 23.
Artículo en Inglés | MEDLINE | ID: mdl-27391157

RESUMEN

The phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway is frequently hyper-activated upon vemurafenib treatment of melanoma. We have here investigated the relationship between SRY-box 10 (SOX10), forkhead box 3 (FOXD3) and microphthalmia-associated transcription factor (MITF) in the regulation of the receptor tyrosine-protein kinase ERBB3, and its cognate ligand neuregulin 1-beta (NRG1-beta). We found that both NRG1-beta and ERBB3 mRNA levels were elevated as a consequence of MITF depletion, induced by either vemurafenib or MITF small interfering RNA (siRNA) treatment. Elevation of ERBB3 receptor expression after MITF depletion caused increased activation of the PI3K pathway in the presence of NRG1-beta ligand. Together, our results suggest that MITF may play a role in the development of acquired drug resistance through hyper-activation of the PI3K pathway.


Asunto(s)
Melanoma/tratamiento farmacológico , Factor de Transcripción Asociado a Microftalmía/fisiología , Neurregulina-1/análisis , Receptor ErbB-3/análisis , Línea Celular Tumoral , Factores de Transcripción Forkhead/análisis , Humanos , Indoles/farmacología , Indoles/uso terapéutico , Melanoma/metabolismo , Factor de Transcripción Asociado a Microftalmía/análisis , Fosfatidilinositol 3-Quinasas/fisiología , Proteínas Proto-Oncogénicas c-akt/metabolismo , Factores de Transcripción SOXE/análisis , Transducción de Señal/fisiología , Sulfonamidas/farmacología , Sulfonamidas/uso terapéutico , Vemurafenib
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...